Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
about
Chondrocyte Apoptosis in the Pathogenesis of OsteoarthritisThe Impact of Neuroimmune Alterations in Autism Spectrum DisorderGenetic and Epigenetic Alterations in Bladder CancerMolecular targets in urothelial cancer: detection, treatment, and animal models of bladder cancerS6K1 and 4E-BP1 are independent regulated and control cellular growth in bladder cancerPleckstrin homology domain of Akt kinase: a proof of principle for highly specific and effective non-enzymatic anti-cancer targetCSTP1, a novel protein phosphatase, blocks cell cycle, promotes cell apoptosis, and suppresses tumor growth of bladder cancer by directly dephosphorylating Akt at Ser473 site.FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.Cyclooxygenase 2-dependent and independent activation of Akt through casein kinase 2α contributes to human bladder cancer cell survival.Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications.Novel neoadjuvant therapy paradigms for bladder cancer: results from the National Cancer Center Institute Forum.Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.Epidermal growth factor receptor expression in urinary bladder cancerAntiproliferative factor signaling and interstitial cystitis/painful bladder syndromeRas signaling contributes to survival of human T-cell leukemia/lymphoma virus type 1 (HTLV-1) Tax-positive T-cells.Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitroUrothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies.Genetic deletion and pharmacological inhibition of Akt1 isoform attenuates bladder cancer cell proliferation, motility and invasion.P2X7 Receptor Function in Bone-Related Cancer.Akt phosphorylates Prohibitin 1 to mediate its mitochondrial localization and promote proliferation of bladder cancer cellsAutophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cellsMonosodium Urate Crystal-Induced Chondrocyte Death via Autophagic Process.DNMT1-dependent suppression of microRNA424 regulates tumor progression in human bladder cancer.Transcriptional Modulation of the ERK1/2 MAPK and NF-κB Pathways in Human Urothelial Cells After Trivalent Arsenical Exposure: Implications for Urinary Bladder Cancer.Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.Loss of Sh3gl2/endophilin A1 is a common event in urothelial carcinoma that promotes malignant behavior.Novel strategies for treating relapsed/refractory urothelial carcinoma.RETRACTED: Integrated gene network analysis and text mining revealing PIK3R1 regulated by miR-127 in human bladder cancer.Detection of multiple mutations in urinary exfoliated cells from male bladder cancer patients at diagnosis and during follow-upGenomic profiling is predictive of response to cisplatin treatment but not to PI3K inhibition in bladder cancer patient-derived xenografts.Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway.Molecular targets on the horizon for kidney and urothelial cancer.PI3K/AKT signaling pathway and cancer: an updated review.Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer.Targeting PI3K/AKT/mTOR network for treatment of leukemia.The Phosphatidylinositol 3-kinase Pathway as a Potential Therapeutic Target in Bladder Cancer.Combination of Rapamycin and Resveratrol for Treatment of Bladder Cancer.mTOR inhibitors in urinary bladder cancer.MiR-126 regulates proliferation and invasion in the bladder cancer BLS cell line by targeting the PIK3R2-mediated PI3K/Akt signaling pathway.LY294002 induces in vitro apoptosis and overexpression of p75NTR in human uterine leiomyosarcoma HTB 114 cells.
P2860
Q26777068-9BBBF6D6-8BB9-4287-BCFA-39180308E9B6Q26781540-29293474-8523-4A64-AAF9-9ADBD32D06B6Q28074732-AFBB30E4-B44B-45E6-AF68-E446F581B11EQ28076041-09D7F5FF-0A17-4182-8A81-C9DBE95DED1AQ28477972-DE5B08D6-AB1F-4DD3-A542-4542DF544D85Q28485326-AD2FB914-884D-46A2-9807-CD61F681BE46Q31120339-EA1F4B22-C66B-41B6-BE34-6C0340CC5A6EQ33745140-A4F91E7C-5ED4-4DFC-A381-AB532397EFBEQ33904650-5D22F0A4-A98D-426D-B7C2-5BE132D1671EQ34566745-0CA33123-4FD7-4911-838A-BFCB6ACC01CDQ34670535-A57DD4FE-0301-40D5-BC5D-B82858CE2092Q34966603-88C9CDA8-2421-4207-8FDF-FB4F89257612Q35125725-1F7BCDE9-7D4A-4B51-96E3-3EE319CD3710Q35667287-7B8E3F42-EA87-4F46-B7A3-B3A2AC1A0349Q35757427-63031A20-D269-41E0-9292-5C487FBF1F9DQ35849100-41155C1A-59B0-4492-A33B-4F02BDB806EEQ36061127-33E44D79-8D13-4513-BBF7-D8524E131167Q36144821-A8B829B3-8D3F-4673-BDD3-49469CC47BB8Q36200053-609CFD1A-A00B-4EC4-BED4-69AF7FE6851FQ36347268-3FCF1C5F-EF7F-49D0-8BDF-E33834BFB476Q36384361-500FBFCC-B5FA-4D4B-B9B1-168D70961E16Q36404177-462C9DCC-0048-401B-888E-4E8EF604EADAQ36414395-1D6913C6-43D7-455D-BDF9-A97AC774A35BQ36672637-CCD5BD43-3540-4342-A07B-5A8B23DFCA2FQ36862768-5B89D8C6-4A14-4FDC-B2EF-D1FC2117161BQ36945929-494AB9D7-8B57-4FF5-A2F7-A9FF89B81000Q36995686-C79E9631-4852-476C-ADAD-9F6C3C7DACD6Q37155055-4B8FDD28-52D6-43FE-94D9-5B689B167AD9Q37687183-50EE86B7-32DA-471F-BD4C-CD7D3D0A9DACQ37718224-0B90D501-7976-498F-8E2B-68EC52C9DCB9Q37775890-B6BB68BC-C7EA-4697-ACF4-5E5DB09B9B19Q38132039-3E6B7C00-7257-4BF7-9E41-A87DDB40B02CQ38217651-781F5633-9D91-459B-9469-84B955A8D798Q38222834-66381D13-E6E1-44A9-BD07-58B54D27139DQ38364871-33CE948B-A1F5-4AFC-A13B-EE78787F9A80Q38694934-F725DA92-8A9F-41BD-B57A-0FEED4F2C490Q38735342-918575EC-BEA9-48B0-8907-3059E2912C2CQ38737064-9071F077-9707-4B28-9AAC-415289842D7EQ38748901-2EBAC976-DAF5-415D-A193-BA92A9E42BA4Q38812870-8F65327A-3252-4E7C-94E2-270FC038F1D2
P2860
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
@ast
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
@en
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
@en-gb
Phosphatidylinositol 3-kinase
@nl
type
label
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
@ast
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
@en
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
@en-gb
Phosphatidylinositol 3-kinase
@nl
prefLabel
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
@ast
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
@en
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
@en-gb
Phosphatidylinositol 3-kinase
@nl
P2093
P2860
P921
P1476
Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer
@en
P2093
Carolyn D Hurst
Fiona M Platt
Rebecca L Ross
P2860
P2888
P304
P356
10.1007/S10555-009-9198-3
P577
2009-12-01T00:00:00Z
P5875
P6179
1040030028